These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12042700)

  • 1. Role of FLT3 in leukemia.
    Gilliland DG; Griffin JD
    Curr Opin Hematol; 2002 Jul; 9(4):274-81. PubMed ID: 12042700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
    Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J
    Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
    Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
    Reilly JT
    Leuk Lymphoma; 2003 Jan; 44(1):1-7. PubMed ID: 12691136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
    Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
    Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
    Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.
    Mizuki M; Schwable J; Steur C; Choudhary C; Agrawal S; Sargin B; Steffen B; Matsumura I; Kanakura Y; Böhmer FD; Müller-Tidow C; Berdel WE; Serve H
    Blood; 2003 Apr; 101(8):3164-73. PubMed ID: 12468433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
    Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T
    Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
    O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
    Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.
    Kelly LM; Liu Q; Kutok JL; Williams IR; Boulton CL; Gilliland DG
    Blood; 2002 Jan; 99(1):310-8. PubMed ID: 11756186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
    Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
    Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
    Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.
    Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.
    Scheijen B; Ngo HT; Kang H; Griffin JD
    Oncogene; 2004 Apr; 23(19):3338-49. PubMed ID: 14981546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations.
    Zheng R; Friedman AD; Small D
    Blood; 2002 Dec; 100(12):4154-61. PubMed ID: 12393674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
    Kelly LM; Yu JC; Boulton CL; Apatira M; Li J; Sullivan CM; Williams I; Amaral SM; Curley DP; Duclos N; Neuberg D; Scarborough RM; Pandey A; Hollenbach S; Abe K; Lokker NA; Gilliland DG; Giese NA
    Cancer Cell; 2002 Jun; 1(5):421-32. PubMed ID: 12124172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor.
    Zhao M; Kiyoi H; Yamamoto Y; Ito M; Towatari M; Omura S; Kitamura T; Ueda R; Saito H; Naoe T
    Leukemia; 2000 Mar; 14(3):374-8. PubMed ID: 10720129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.